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Exosomes are endosomal-derived nanovesicles released by normal and tumor cells, which
transfer functionally active proteins, lipids, and nucleic acids between cells.They are impor-
tant mediators of intercellular communication and act on the adjacent stroma as well as in
the periphery. Recently, exosomes have been recognized to play a pathophysiological role in
various diseases such as cancer or infectious diseases.Tumor cell-derived exosomes (Tex)
have been shown to act as tumor promotors by educating non-malignant cells to provide a
tumor supporting microenvironment, which helps to circumvent immune detection by the
host and supports metastasis. However,Tex with anti-tumor, immune-activating properties
were also described reflecting the complexity of exosomes. Here, we assess the role of
extracellular microvesicles/exosomes as messengers affecting NK cell function in health
and disease and discuss the molecular basis for the differential impact of exosomes on NK
cell activity. The molecular composition/load of exosomes and the mechanisms regulating
their release remain unclear and need to be further analyzed to facilitate the development
of new treatment options targeting the exosomal machinery.
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INTRODUCTION
Intercellular communication is a prerequisite for a functional
immune surveillance in order to obtain a healthy organism. Virus
infected or malignant cells are identified and eliminated by the
immune system via membrane bound or secreted molecules.
Besides these well-known pathways of cell–cell communication
the impact of endosomal-derived microvesicles, so called exo-
somes, has emerged as another important mechanism to regulate
the immune response.
The function of exosomes was originally attributed to the elim-
ination of obsolete proteins, however, it became quite clear that
these vesicles are important mediators of intercellular communi-
cation. Exosomes are a homogeneous group of nanovesicles with
a size of approximately 50–100 nm. They are budded into the
limiting membrane of endosomes to form multivesicular bodies
(MVB). The fusion of the MVB with the plasma membrane leads
to the release of the intraluminal vesicles into the extracellular
space.
Exosomes are specifically loaded with membrane and cytosolic
proteins as well as nucleic acids, depending on the originating cell
and its homeostatic state. This results in the formation of func-
tionally distinct exosomes and their activity ranges from immune
activation to immune suppression or induction of tolerance. How-
ever, the mechanisms that regulate the exosomal release and the
sorting of specific molecules in exosomes are far from being under-
stood. In this perspective, we focus on the interaction of exosomes
with NK cells.
DENDRITIC CELL-DERIVED EXOSOMES: POTENT
ACTIVATORS OF NK CELLS
The ability to activate NK cells has been primarily reported for exo-
somes derived from dendritic cells (DCs). Dendritic cell-derived
exosomes (Dex) can directly trigger NK cell activation in mice and
cancer patients. The interaction of TNF expressed on Dex with
the corresponding TNF receptors on NK cells induced interferon-
γ (IFNγ) secretion from NK cells. These data demonstrate that
Dex can mediate essential innate immune functions – a feature
that was previously ascribed to DCs themselves (1). The use of
Dex in clinical phase I trials was reported to trigger NK cells in
half of the patients (2–4), but the underlying mechanisms for the
Dex bioactivity on NK cells remained unclear. In 2009, Viaud et al.
showed that membrane bound ligands for NKG2D as well as IL-
15Ra seemed to play an essential role in Dex-induced activation
of NK cells in humans and mice (5). Thereby, Dex triggered an
IL-15Ra and NKG2D-dependent NK cell proliferation and activa-
tion in secondary lymphoid organs in mice. A first phase I clinical
study with 15 melanoma patients supported the notion that Dex
vaccines significantly enhanced the number of circulating NK cells
and restored their NKG2D expression levels (5). Furthermore,
exosomes released from DCs expressed BAG6, a ligand for the
activating NK cell receptor NKp30. BAG6-expressing exosomes
induced NK cell-mediated cytokine release and cytotoxicity, indi-
cating a role for exosomes released from DCs to initiate the innate
function of NK cells (6). The exosomal release of danger signals
that alert NK cells may be considered as priming signal and sup-
ports a two-step activation model of human NK cells involving a
priming and a triggering event.
As Dex also express functional MHC molecules and T cell co-
stimulatory molecules such as CD40, CD80, and CD86 (4), they
are also potent T cell activators (reviewed elsewhere). In addition,
Dex can directly mediate tumor cell killing via Fas-L and TRAIL
(1). This combination of direct anti-tumor and immune stimula-
tory activity seem to make Dex ideal tools for cancer treatment.
Nevertheless, Dex therapies were so far not expanded into the
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clinical routine. This might be attributed to technical difficulties
to produce sufficient amounts of exosomes with defined proper-
ties. A better basic understanding of the regulation, biosynthesis,
and specific protein and RNA cargo of exosomes from different cell
types and environments would definitely inspire the development
of novel therapies, which might in the end be based on in vivo
modulation of exosome release and function. This holds also
true for exosomes released from tumor cells (Tex). Tumor-derived
exosomes are predominantly described as immune-suppressing
vesicles, however, there are also reports of anti-tumor immune-
activating Tex. As soon as we understand the signals directing the
formation of functional distinct exosomes, we can proceed and
modify the exosomes and their release therapeutically to retain
their anti-tumor activity.
TUMOR CELL-DERIVED EXOSOMES: BENEFIT OR DANGER?
Tumor cells develop a number of mechanisms to escape or sup-
press an active immune response such as down-regulation of
surface MHC molecule expression (7), secretion of immune-
inhibitory cytokines (8) or by regulating stromal components to
generate a tumor growth promoting microenvironment (9).
More recently, the impact of tumor cell-derived exosomes
on immune surveillance has been discussed. While the effect of
tumor cell-derived exosomes (Tex) on T cells is extensively inves-
tigated, little is published on the direct impact of Tex on NK
cell function. Unlike for Dex, Tex are discussed to be immune-
activating as well as immune-inhibitory, although reports on Tex
with immune-stimulating function are clearly outnumbered by
studies indicating an inhibitory effect on the immune response.
TEX AS IMMUNE STIMULATORS
As Tex have the ability to express tumor-associated antigens, they
play a role in cancer immunology, such as transport of antigens
to DCs to initiate an anti-tumor immune response via cross-
presentation (10, 11). HepG2 and PLC/PRF/5 cell lines were used
as models to study heat shock protein (Hsp)-bearing exosome
secretion by hepatocellular carcinoma cells under stress condi-
tions (12). Their results showed that incubation of NK cells with
Hsp-bearing exosomes augmented cytolytic activity against K562
or HepG2 target cells through granzyme B release; up-regulation
of activating receptors CD69, NKG2D, and NKp44; and down-
regulation of inhibitory receptor CD94. This seemed to be depen-
dent not only on exosome concentration but also on Hsp expres-
sion, with notably higher Hsp expression on HepG2-released
exosomes after treatment with chemotherapeutics. Interestingly,
treatment with resistant anti-cancer drugs seemed to enhance Hsp
expression on exosomes more efficiently than sensitive chemother-
apeutics, leading to a more pronounced NK cell activation (12).
This is in line with findings of Gastpar and colleagues, who showed
that NK cells were stimulated by human pancreas and colon carci-
noma sublines-derived exosomes, depending on their capacity to
present heat shock protein 70 (Hsp70)/Bag-4 on their membranes.
Natural killer cells were stimulated selectively by Hsp70/Bag-4
surface-positive exosomes; an effect that could be blocked with
Hsp70-blocking antibody (13). BAG6, another Hsp70-interacting
protein, is known to engage the activating NK cell receptor NKp30
and BAG6-expressing exosomes trigger NK cell-mediated cytokine
release and cytotoxicity (14, 15). Moreover, Tex may induce the
up-regulation of granzyme B, IL-2, IFNγ, TNFα, CD25, and
reduce CD95L expression in NK cells (16), further arguing for
Tex-supported NK cell activation.
Still, Tex are mostly described as inhibitors of the immune
system supporting tumor immune evasion, indicating that the for-
mation of NK cell-activating exosomes may depend on the tumor
cell type, state of tumor progression, and the microenvironment,
factors that still need to be defined.
TEX AS IMMUNE INHIBITORS
Several reports state an immune suppressive effect of tumor cell-
derived exosomes on NK cells. This effect is frequently associated
with an altered surface protein expression. Often, ligands for the
activating NK cell receptor NKG2D are being identified as crucial
factors.
Clayton et al. demonstrated that NKG2D is down regulated
on CD3-positive peripheral blood leukocytes following exposure
to tumor-derived exosomes, resulting in an impaired cytotoxic
effector function of the CD8+ T cells (17). This effect was depen-
dent on the exosomal expression of NKG2D ligands (NKG2D-L)
and could be abolished by blocking with corresponding NKG2D
ligand antibodies. Yet, in this study the effects of Tex were only
detected on T cells, but not proven for CD3-negative PBL. Sub-
sequent publications indicate that NKG2D-L-bearing exosomes
can have similar effects on NK cells. For instance, incubation of
NK cells with MICA-containing exosomes provokes an NKG2D-
dependent reduction of NK cell cytotoxicity independent of
NKG2D-L expression by the target cell (18). In a further study,
NKG2D-L-expressing tumor-derived exosomes showed a direct
interaction with NK cells and CD8+ T cells leading to a signifi-
cant reduction in cell surface NKG2D expression (19). This was
at least partly dependent on NKG2D-L; however, in this study the
impact of exosomal TGFbeta1 on the observed effects was much
stronger. Exosome-mediated down-modulation of NKG2D corre-
lated with poor functional responses, as the interaction resulted
in an impaired cytolytic function of NK cells. Thus, the effi-
ciency of Tex might reflect their specific feature to display multiple
inhibitory signals at once and by this being able to even overcome
pro-inflammatory signals. This is in line with findings reporting
an inhibition of IL-2-mediated up-regulation of CD25 by tumor
exosomes selectively in NK cells and CD8+ T cells (20). At the same
time, CD4+CD25+ Treg cells remained IL-2 responsive and their
inhibitory function was enhanced by tumor exosomes. Liu and
colleagues showed that exosomes derived from murine mammary
carcinoma cell lines inhibit NK cell cytotoxic activity ex vivo and
in vitro. Key features of NK cell activity were inhibited, including
release of perforin but not granzyme B, as well as the expression
of cyclin D3 and activation of Jak3-mediated pathways. Human
tumor cell lines were also found to produce exosomes that were
capable of inhibiting IL-2-stimulated NK cell proliferation. Thus,
it was proposed that tumor exosomes contribute to the growth of
tumors by blocking IL-2-mediated activation of NK cells and their
cytotoxic response to tumor cells (21).
Clinical observations revealed that sera of acute myeloid
leukemia (AML) patients have higher levels of microvesicles with
an explicit molecular profile expressing membrane-associated
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FIGURE 1 | Exosomes released from stressed or neoplastic cells can
lead to NK cell activation or inhibition, which depends on a
differential molecular composition. Immune-activating exosomes (e.g.,
Dex) often express TNF and can induce INFγ secretion and enhance
cytolytic activity of NK cells. In contrast, immune suppressive exosomes
often contain TGFbeta1 and NKG2D ligands and inhibit NK cell cytotoxicity.
Cellular stress and mutagenesis affect the biogenesis of functional distinct
exosomes. Although several features attributed to one or the other effect
are described, the mechanisms leading to the respective exosome
formation are still poorly understood. A major question remaining to be
answered is how stress and mutagenesis affect the different sorting
mechanisms responsible for the genesis of immune-activating or
-suppressive vesicles. As soon as the determining pathways and their
regulation are comprehensively explored, the exosome cargo will become
more predictable and allow the development of new, astute strategies to
employ exosomes as therapeutic tools.
TGFbeta1, MICA/MICB, and the myeloid blast markers CD34,
CD33, CD117 (22). Again, TGFbeta1 seemed the prominent factor
to induce immune suppression by decreasing NK cell cytotoxicity
and down-regulation of NKG2D expression. In this setting, treat-
ment with IL-15 protected NK cells from adverse effects of tumor-
derived microvesicles. Findings on exosomes/microvesicles iso-
lated from solid tumors or AML patient sera and their modulatory
functions on different immune cells were recently summarized and
comprehensively reviewed (23). In gastric cancer patients, elevated
Fas levels have been detected on tumor-infiltrating as well as circu-
lating NK cells. This was closely related to a significantly increased
NK cell apoptosis (24). Thus, exosomes expressing death receptor
ligands might not only be able to kill T cells (25–27) but it seems
quite likely that they will have similar effects on NK cells.
Taken together, via diverse mechanisms acting in concert, Tex
potentially contribute to an immunosuppressive environment,
emphasizing their physiological importance for tumor immune
escape. The activity of NKG2D-L on Tex is obviously contra-
dictory to the NKG2D-L activity on Dex, which are known to
activate NK cells. This reflects the context-dependent impact of
a given molecule on exosomes – which further strengthens the
need for a better basic understanding of exosome regulation and
formation.
EXOSOME CARGO FORMATION
In summary, the composition of exosomes with proteins and
nucleic acids seems to be decisive regarding their ability to inhibit
or promote an immune response. Most likely, the sorting is not
solely modulated by the transported protein itself, as NKG2D-
L are nicely targeted to exosomes in the breast cancer cell line
T47d, whereas exosomes of the strongly NKG2D-L positive T cell
lymphoma line Jurkat are completely NKG2D-L negative (17).
Ashiru et al. stated a putative sorting mechanism for the NKG2D-L
MICA. They speculate that the specific translocation of MICA*008
into exosomes is in contrast to other MICA/B molecules due to
its difference in the predicted transmembrane and cytoplasmic
domains (18). Recently, the group was able to demonstrate that
GPI modification of MICA*008 is responsible for the recruit-
ment into exosomes (28). Nevertheless, today it is still little known
about the mechanisms of protein sorting into exosomes. Some
exosomal proteins are sorted by the ubiquitin pathway (29, 30).
Current findings suggest that tetraspanin-enriched microdomains
may act as compartmentalizing platforms that aid the selection of
some intracellular components toward exosomes, as genetic dele-
tion of the tetraspanin CD81 impaired the inclusion of a number
of selective CD81-binding proteins into exosomes (31). Further-
more, the contribution of the ESCRT (endosomal sorting complex
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required for transport)-machinery is discussed (32–34). It was
also stated that the formation of proteolipid protein-containing
exosomes does not require the ESCRT machinery, but sphin-
golipid ceramide and the activity of the neutral sphingomyelinase
(35). Proteins expressed on exosomes do not share a general
exosome-targeting amino acid motif, but are rather characterized
by a broad range of sequence motifs that confer plasma mem-
brane binding and higher-order oligomerization (36). This might
be different for the specific loading of RNA species into exo-
somes. Recently it was reported that A2B1 (heterogeneous nuclear
ribonucleoprotein hnRNPA2B1) specifically recognizes and binds
sequence motifs present in miRNAs to control their packaging into
exosomes (37).
However, the signaling pathways that direct the specific loading
of proteins and nucleic acids of different cell types in response
to the cell status and environment remain largely unknown
(see Figure 1). Recently, it was shown that viral stress sig-
nals may alter the composition of exosomes and by this can
change their immune-modulatory capacity. The activation of
the cytosolic pattern recognition receptor (PRR) RIG-I with
its respective ligand leads to an enhanced release of NK cell-
activating exosomes from melanoma cells. Thus, former tumor-
promoting exosomes were transformed to immune-activating,
anti-tumor immune agents. This pathway establishes a novel
and unexpected link of a PRR and the release of exosomes
(Dassler and Reiners, unpublished work). In this context, the
impact of TLR activation on exosome release and characteristics
seems an interesting topic that deserves to be studied in more
detail.
CONCLUSION
The multiple functions of exosomes make them somewhat dou-
ble edged features for new therapeutic strategies: on the one
hand, they appear to be especially suitable, as they may be selec-
tively loaded with optimal drug combinations, have an excellent
biodistribution and biocompatibility and can act with different
mechanisms at once. On the other hand, to employ exosomes as
anti-tumor reagent, a better understanding on exosomes target
selection is required to improve therapeutic exosome application.
Exosomes are suggested to bind to and be taken-up by selected
targets (18). For instance, exosomes are rich in tetraspanins and
some studies suggest exosomal tetraspanin–integrin complexes to
be involved in target cell binding (38). Rana et al. were able to show
that even minor differences in exosomal tetraspanin-complexes
strongly influence target cell selection in vitro and in vivo. Their
report on the contribution of exosomal tetraspanins to target cell
selection is one step toward the ability to predict potential target
cells.
As long as we do not thoroughly understand the mechanisms of
protein (and nucleic acid) sorting into exosomes, the outcome of
any new therapeutic strategy involving exosomes will be sparsely
predictable. Only the basic knowledge on how the molecular com-
position of exosomes is determined and how exosome biogenesis is
influenced by cell status, the environment or signaling will enable
us to develop new, innovative strategies with exosomes as tools or
targets.
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